References
- Abboud MR. 2020. Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. 13(2):85–90.
- Arimany-Nardi C, Errasti-Murugarren E, Minuesa G, Martinez-Picado J, Gorboulev V, Koepsell H, Pastor-Anglada M. 2014. Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Br J Pharmacol. 171(16):3868–3880.
- Beumer JH, Eiseman JL, Parise RA, Florian JA Jr., Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ. 2008a. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol. 62(3):457–464.
- Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ. 2008b. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol. 62(2):363–368.
- CDC. 2020. Data & statistics on sickle cell disease; [accessed 2021 Jan 12]. https://www.cdc.gov/ncbddd/sicklecell/data.html
- Charache S, Dover G, Smith K, Talbot CC Jr., Moyer M, Boyer S. 1983. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci USA. 80(15):4842–4846.
- Cohen RM, Wolfenden R. 1971. Cytidine deaminase from Escherichia coli: purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J Biol Chem. 246(24):7561–7565.
- Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, Tong Z. 2012. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids. 31(3):236–255.
- DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, et al. 2019. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 133(1):7–17.
- EMA. 2008. Hydroxycarbamide (Siklos) EPAR – product information; [accessed 2020 Nov 24]. https://www.ema.europa.eu/en/documents/product-information/siklos-epar-product-information_en.pdf
- EMA. 2012a. Dacogen Assessment report (EMA/620205/2012); [accessed 2020 Nov 18]. https://www.ema.europa.eu/en/documents/assessment-report/dacogen-epar-public-assessment-report_en.pdf
- EMA. 2012b. Guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2); [accessed 2020 Nov 24]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
- EMA. 2017. Public summary of opinion on orphan designation – decitabine and tetrahydrouridine for the treatment of sickle cell disease (EMA/324973/2017); [accessed 2021 Jan 12]. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1881-public-summary-opinion-orphan-designation-decitabine-tetrahydrouridine-treatment-sickle-cell_en.pdf
- EMA. 2019. Decitabine (Dacogen®): EPAR – product information; [accessed 2021 Jan 13]. https://www.ema.europa.eu/en/documents/product-information/dacogen-epar-product-information_en.pdf
- EMA. 2021. Crizanlizumab (Adakveo) – EPAR product information; [accessed 2021 Jan 12]. https://www.ema.europa.eu/en/documents/product-information/adakveo-epar-product-information_en.pdf
- FDA. 2017. L-glutamine (EndariTM) – prescribing information; [accessed 2020 Nov 24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf
- FDA. 2018. Decitabine (DACOGEN®) – prescribing information; [accessed 2021 Jan 13]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf
- FDA. 2019a. Crizanlizumab-tmca (ADAKVEO®) – prescribing information; [accessed 2021 May 5]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
- FDA. 2019b. Venetoclax (VENCLEXTA®) – prescribing information; [accessed 2021 Nov 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s013lbl.pdf
- FDA. 2019c. Voxelotor (OXBRYTA™) – prescribing information; [accessed 2020 Nov 24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf
- FDA. 2020. In vitro drug interaction studies – cytochrome P450 enzyme and transporter-mediated drug interactions – guidance for industry; [accessed 2020 Nov 24]. https://www.fda.gov/media/134582/download
- Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9(3):215–236.
- Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD. 2007. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol. 293(5):R1809–R1822.
- Jordheim LP, Durantel D, Zoulim F, Dumontet C. 2013. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 12(6):447–464.
- Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, et al. 2018. Sickle cell disease. Nat Rev Dis Primers. 4:18010.
- Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S, et al. 1991. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)–a pilot study. Leukemia. 5(11):991–998.
- Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, et al. 2012. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood. 119(5):1240–1247.
- Liang Y, Li S, Chen L. 2015. The physiological role of drug transporters. Protein Cell. 6(5):334–350.
- Manwani D, Frenette PS. 2013. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 122(24):3892–3898.
- Marsh JH, Kreis W, Barile B, Akerman S, Schulman P, Allen SL, DeMarco LC, Schuster MW, Budman DR. 1993. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol. 31(6):481–484.
- Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, et al. 2017. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 14(9):e1002382.
- Paikari A, Sheehan VA. 2018. Fetal haemoglobin induction in sickle cell disease. Br J Haematol. 180(2):189–200.
- Piel FB, Steinberg MH, Rees DC. 2017. Sickle cell disease. N Engl J Med. 376(16):1561–1573.
- Saunthararajah Y. 2019. Targeting sickle cell disease root-cause pathophysiology with small molecules. Haematologica. 104(9):1720–1730.
- Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. 2014. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 123(4):481–485.
- Varga A, Lionne C, Roy B. 2016. Intracellular metabolism of nucleoside/nucleotide analogues: a bottleneck to reach active drugs on HIV reverse transcriptase. Curr Drug Metab. 17(3):237–252.